See more : Medtecs International Corporation Limited (9103.TW) Income Statement Analysis – Financial Results
Complete financial analysis of PPD, Inc. (PPD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PPD, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- LDH Growth Corp I (LDHAW) Income Statement Analysis – Financial Results
- Medibio Limited (MDBIF) Income Statement Analysis – Financial Results
- Guangzhou Fangbang Electronics Co.,Ltd (688020.SS) Income Statement Analysis – Financial Results
- Palfinger AG (PLFRY) Income Statement Analysis – Financial Results
- R.P.P. Infra Projects Limited (RPPINFRA.NS) Income Statement Analysis – Financial Results
PPD, Inc. (PPD)
About PPD, Inc.
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
Metric | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|
Revenue | 4.68B | 4.03B | 3.75B | 3.00B | 2.68B |
Cost of Revenue | 2.88B | 2.41B | 2.27B | 1.54B | 1.39B |
Gross Profit | 1.80B | 1.62B | 1.47B | 1.46B | 1.29B |
Gross Profit Ratio | 38.42% | 40.24% | 39.32% | 48.80% | 48.25% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
Operating Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
Cost & Expenses | 4.17B | 3.61B | 3.35B | 2.74B | 2.37B |
Interest Income | 0.00 | 0.00 | 5.45M | 3.55M | 2.51M |
Interest Expense | 216.93M | 311.74M | 263.62M | 253.89M | 203.29M |
Depreciation & Amortization | 279.12M | 264.83M | 258.97M | 279.07M | 260.49M |
EBITDA | 668.54M | 627.35M | 666.36M | 544.62M | 630.92M |
EBITDA Ratio | 14.28% | 15.56% | 17.77% | 18.15% | 23.55% |
Operating Income | 509.43M | 418.49M | 402.24M | 261.33M | 314.26M |
Operating Income Ratio | 10.88% | 10.38% | 10.73% | 8.71% | 11.73% |
Total Other Income/Expenses | -321.88M | -359.21M | -255.61M | -244.86M | -147.37M |
Income Before Tax | 187.55M | 59.28M | 146.63M | 16.47M | 166.89M |
Income Before Tax Ratio | 4.01% | 1.47% | 3.91% | 0.55% | 6.23% |
Income Tax Expense | 18.81M | 2.96M | 39.58M | -284.36M | -15.96M |
Net Income | 153.69M | 47.82M | 104.19M | 296.03M | 183.10M |
Net Income Ratio | 3.28% | 1.19% | 2.78% | 9.86% | 6.83% |
EPS | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
EPS Diluted | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
Weighted Avg Shares Out | 346.68M | 339.43M | 324.30M | 325.04M | 324.22M |
Weighted Avg Shares Out (Dil) | 346.68M | 339.43M | 324.30M | 325.86M | 324.30M |
FINAL PPD DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds PDD Holdings Inc. f/k/a Pinduoduo Inc. Investors to Join the Class Action Lawsuit!
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results
Thermo Fisher Scientific's PPD Clinical Research Business Earns TOPRA Award for Regulatory Affairs Excellence in Supporting Novavax's COVID-19 Vaccine Approval
Saama Appoints Scott Rogers as Company's Chief Financial Officer
Thermo Fisher Scientific Completes Acquisition of PPD, Inc.
PPD Named to ‘Best Workplaces in Greater China’ for Second Consecutive Year
PPD Named to ‘Best Workplaces in Greater China' for Second Consecutive Year
PPD 连续第二年荣膺2021年度“大中华区最佳职场TM”称号
PPD 連續第二年榮膺2021年度「大中華區最佳職場TM」稱號
Source: https://incomestatements.info
Category: Stock Reports